GOVERNMENT OF NEPAL
MINISTRY OF HEALTH AND POPULATION
DEPARTMENT OF DRUG ADMINISTRATION
1748, Madan Bhandari Path-4
Bijuli Bazar, Kathmandu

Ref. No.: 3555

Date: 29th March, 2019

M/s Bafna Pharmaceuticals Pvt. Ltd,
Chennai, India.

Subject: Report on GMP Audit

Based on the inspection (dated July 17, 2018) conducted by the audit team at your facility located at Chennai, India, we are pleased to inform you that your manufacturing site satisfies the requirements of WHO GMP guidelines for **General products (tablets and capsules)**.

We appreciate your interest to register and market products in Nepal. The audit report is attached herewith for your notice and necessary improvement.

.....
Narayan Prasad Dhakal
Director General
Director General

C.C
1. M/s Registration Division, Department of Drug Administration.
2. M/s Sijal Pharma Pvt. Ltd.